Valuation Takeda Pharmaceutical Company Limited Deutsche Boerse AG
Stocks
TKD
JP3463000004
Pharmaceuticals
|
Real-time Estimate
Tradegate
10:59:31 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 31.10 EUR | +0.61% |
|
-0.55% | +19.24% |
| 04:26am | Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer | MT |
| 11:42pm | Takeda Pharmaceutical Wins US Approval for New PV Treatment MIMRYLO | MT |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,948,061 | 9,261,201 | - | - |
| Change | - | 24.68% | -2.93% | 2.82% | 32.57% | 3.5% | - | - |
| Enterprise Value (EV) 1 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 5,130,461 | 13,167,718 | 12,964,408 | 12,657,368 |
| Change | - | 18.97% | 3.2% | -2.06% | -52.16% | 156.66% | -1.54% | -2.37% |
| P/E | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 46.3x | 29.7x | 24.3x |
| PBR | 0.95x | 1.06x | 0.9x | 1x | 1.2x | 1.24x | 1.24x | 1.24x |
| PEG | - | 0.5x | -0.8x | -2.5x | 0.6x | 16.73x | 0.5x | 1.1x |
| Capitalization / Revenue | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 1.97x | 1.94x | 1.89x |
| EV / Revenue | 2.5x | 2.63x | 2.57x | 2.34x | 1.14x | 2.8x | 2.72x | 2.59x |
| EV / EBITDA | 8.54x | 9.19x | 11.6x | 9.71x | 4.54x | 9.9x | 9.13x | 8.53x |
| EV / EBIT | 19.4x | 21.6x | 51.1x | 31.3x | 12.6x | 29.4x | 21.8x | 18.4x |
| EV / FCF | 8.92x | 28.7x | 43.4x | 15.5x | 8.14x | 18.4x | 18.5x | 17.3x |
| FCF Yield | 11.2% | 3.49% | 2.31% | 6.43% | 12.3% | 5.43% | 5.4% | 5.78% |
| Dividend per Share 2 | 180 | 180 | 188 | 196 | 200 | 204.3 | 208.4 | 214.9 |
| Rate of return | 5.15% | 4.14% | 4.49% | 4.44% | 3.53% | 3.52% | 3.59% | 3.71% |
| EPS 2 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 125.4 | 195.3 | 238.8 |
| Distribution rate | 122% | 88.1% | 204% | 287% | 164% | 163% | 107% | 90% |
| Net sales 1 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,694,598 | 4,772,892 | 4,892,621 |
| EBITDA 1 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,330,479 | 1,420,133 | 1,484,285 |
| EBIT 1 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 448,525 | 595,763 | 686,473 |
| Net income 1 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 195,073 | 318,478 | 377,294 |
| Net Debt 1 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | -3,817,600 | 3,906,517 | 3,703,207 | 3,396,167 |
| Reference price 2 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,664.00 | 5,800.00 | 5,800.00 | 5,800.00 |
| Nbr of stocks (in thousands) | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,813 | 1,596,759 | - | - |
| Announcement Date | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/13/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.44x | 12.14x | 24.6x | 0.59% | 1,047B | |
| 29.82x | - | - | 2% | 646B | |
| 32.61x | 7.57x | 15.74x | 2.68% | 451B | |
| 19.99x | 4.75x | 11.76x | 2.79% | 355B | |
| 21.76x | 5.62x | 13.93x | 2.85% | 291B | |
| 20.88x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.35x | 7.07x | 12.56x | 2.33% | 234B | |
| 13.25x | 4.77x | 9.95x | 3.83% | 203B | |
| -44.51x | 6.43x | 25.11x | 2.26% | 181B | |
| Average | 17.17x | 6.58x | 15.74x | 2.38% | 406.59B | |
| Weighted average by Cap. | 24.24x | 8.07x | 17.81x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4502 Stock
- TKD Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
